We are live on ! Find out more
PRTC

PureTech Health

Delisted

PRTC was delisted on the 20th of May, 2026.

3 hedge funds and large institutions have $2.4M invested in PureTech Health in 2023 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

49,175% more capital inflows, than outflows

Capital inflows: $13.8K | Capital outflows: $28

0% more funds holding

Funds holding: 3 → 3 (0)

0% more ownership

Funds ownership: 0.29% → 0.29% (+0%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$13.8K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$28

PRTC Hedge Fund Activity: Q2 2023 in Review

3 of the 6,391 institutional investors tracked by Wall St. Rank reported a position in PureTech Health (PRTC) for Q2 2023, worth a combined $2.4M — up 4.6% from $2.29M a quarter earlier.

Fund positioning in PRTC was balanced in Q2 2023: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Jane Street, adding an estimated $13.8K. The largest seller was UBS Group, cutting an estimated $28.

  • 3 institutional investors held PureTech Health (PRTC) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $2.4M of PureTech Health stock for Q2 2023, up 4.6% quarter-over-quarter.
  • 0 funds opened new PureTech Health positions in Q2 2023 and 0 closed out.
  • The largest PureTech Health buyer in Q2 2023 was Jane Street, an estimated $13.8K added.
  • The largest PureTech Health seller in Q2 2023 was UBS Group, an estimated $28 sold.

Based on aggregated 13F filings for Q2 2023.